Know the code/
Target specific small molecules to control infections due to Trypanosomatids
Infectious diseases imposed by the parasites of Trypanosomatidae family continue to represent a huge problem on people’s lives and causes human suffering especially in developing countries. Problems associated with currently available drugs are inefficient delivery, insufficient efficacy, excessive toxicity and steady loss of effectiveness due to increasing resistance of the parasites. New drugs are urgently needed now and in the foreseeable future. Availability of the genome sequence of pathogens of this family offers a unique avenue for identification of novel drug targets and opportunities for the target based discoveries of new lead compounds.
By using a comparative genomic approach we have identified two common and potential targets against Trypanosomatidae family members with no human homologue to avoid potential toxicity issues. The objectives in this project will be to identify new ligands (India), synthesize focused-ligand libraries (Italy), test and validate them in vitro biochemical and cell based assays as well as their effect on the immune system (Portugal, and Spain). Drug delivery systems, based on liposomal and nano-particles formulations, specific to Trypanosomatidae will be developed (Portugal).
TRICONT is focused on collaborative efforts taking into account the priority set in the area of bioinformatics for health by proposing a drug discovery strategy that takes clearly advantage of the genome-based discovery of two new targets.